
    
      Many agents have been given for treatment of COVID-19 infection. "Covid-19 Diagnosis and
      Treatment Guideline" by Ministry of Health was advised nationwide use of favipiravir or
      lopinavir-ritonavir although evidence was scarce for the nationwide use of
      lopinavir-ritonavir or favipiravir to treat COVID-19 at the time of publication date of
      detailed guideline Favipiravir is a RNA dependent RNA polymerase inhibitor and approved for
      treatment of influenza in Japan at 2014 The aim of the study was to compare ICU and hospital
      mortality in patients with favipiravir or lopinavir-ritonavir treatment and compare other
      laboratory parameters in patients treated with these two antiviral agents.
    
  